Amneal Pharmaceuticals, Inc.
AMRX
$17.09
$0.040.24%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.12B | 3.05B | 3.02B | 2.93B | 2.85B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.12B | 3.05B | 3.02B | 2.93B | 2.85B |
| Cost of Revenue | 1.88B | 1.85B | 1.89B | 1.84B | 1.79B |
| Gross Profit | 1.24B | 1.19B | 1.13B | 1.09B | 1.07B |
| SG&A Expenses | 571.88M | 547.42M | 526.85M | 509.16M | 490.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.48M | -182.00K | -5.24M | -5.21M | -5.12M |
| Total Operating Expenses | 2.62B | 2.58B | 2.60B | 2.55B | 2.47B |
| Operating Income | 495.15M | 461.17M | 420.70M | 384.23M | 378.80M |
| Income Before Tax | 201.18M | 181.90M | 139.21M | 68.66M | 89.30M |
| Income Tax Expenses | -14.14M | 584.00K | 11.28M | 11.04M | 38.06M |
| Earnings from Continuing Operations | 215.32 | 181.32 | 127.93 | 57.62 | 51.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -57.96M | -59.20M | -55.88M | -51.72M | -47.87M |
| Net Income | 157.36M | 122.12M | 72.06M | 5.90M | 3.38M |
| EBIT | 495.15M | 461.17M | 420.70M | 384.23M | 378.80M |
| EBITDA | 689.44M | 667.78M | 644.27M | 624.71M | 624.16M |
| EPS Basic | 0.50 | 0.39 | 0.23 | 0.02 | 0.01 |
| Normalized Basic EPS | 0.36 | 0.29 | 0.21 | 0.09 | 0.03 |
| EPS Diluted | 0.49 | 0.38 | 0.23 | 0.02 | 0.01 |
| Normalized Diluted EPS | 0.35 | 0.28 | 0.21 | 0.08 | 0.03 |
| Average Basic Shares Outstanding | 1.26B | 1.26B | 1.25B | 1.25B | 1.24B |
| Average Diluted Shares Outstanding | 1.31B | 1.30B | 1.30B | 1.28B | 1.27B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |